Bicyclic 9a-azalide derivatives
AssigneeEnanta Pharmaceuticals, Inc.
InventorsYat Sun Or, Yao-Ling Qiu, Guoqiang Wang, Deqiang Niu, Ly Tam Phan
Life of this patent
Estimating the term…
Abstract
The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
Claims22
A compound represented by formula (I) or (II):
- as well as the pharmaceutically acceptable salts, and esters thereof, wherein V is selected from the group consisting of:
- (a) —CH2—C(A)=C(B)-CH2—;
- wherein,
- A and B are independently selected from the group consisting of:
- (i) hydrogen;
- (ii) deuterium;
- (iii) halogen;
- (iv) R1, wherein R1 is dependently selected from C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, containing 0, 1, 2 or 3 heteroatoms selected from O, S or N, optionally substituted with one or more substituents selected from the group consisting of:
- halogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
- (v) R2, wherein R2 is independently selected from the group consisting of:
- a. aryl;
- b. heteroaryl;
- c. substituted aryl;
- and
- d. substituted heteroaryl;
- (vi) —(C1-C3-alkyl)-M-(C1-C3-alkyl)-R2, wherein M=—O—, —NH—, —N(CH3)—, —NHC(O)—or —S(O)n—, wherein n =0, 1 or 2, and R2 is as previously defined;
- (vii) —(C1-C3-alkyl)-M-R2, wherein M and R2 are as previously defined;
- (viii) —C(O)-J-R3, wherein J is absent, O or S, and R3 is H, R1 or R2;
- where R1 and R2 are as previously defined, and
- (ix) —C(O)—NR4R5, wherein R4 and R5 are each independently selected from the group consisting of:
- a. hydrogen;
- b. R1, wherein R1 is as previously defined;
- c. R2, wherein R2 is as previously defined;
- and
- d. R4 and R5 taken together with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain one or more heterofunctions selected from the group consisting of:
- —O—, —NH—, —N(R1)—, —N(R2)—, —S(O)n—, wherein n, R1 and R2 are as previously defined;
- (b) —CH2—CH(A)-C(B)═CH—, wherein A and B are as previously defined;
- (c) —CH═C(A)-CH(B)-CH2—, wherein A and B are as previously defined;
- (d) —CH2—CH(A′)-CH(B′)-CH2—;
- wherein A′ and B′ are independently selected from the group consisting of:
- (i) A, wherein A is as previously defined;
- (ii) —OH;
- (iii) —ORp, wherein Rp is a hydroxy protecting group;
- (iv) —O—R9, wherein R9 is R1 or R2, and wherein R1 and R2 are as previously defined;
- (v) —S(O)nR9, wherein n and R9 are as previously defined;
- (vi) —NHC(O)R3, wherein R3 is as previously defined;
- (vii) —NHC(O)NR4R5, wherein R4 and R5 are as previously defined;
- (viii) —NHS(O)2R9, wherein R9 is as previously defined;
- (ix) —NHR13, wherein R13 is an amino protecting group;
- and
- (x) —NR4R5, wherein R4 and R5 are as previously defined;
- wherein:
- (i) -Q- is selected from the group consisting of:
- —O—;
- —O—C(O)—CH(R7)—;
- —N(R7)—;
- —O—C(O)—N(R7)—;
- —O—C(O)—O—;
- —N(R7)—N═N—;
- —C(R7)═N—O—;
- and —CH(R7)—N(R8)—O—;
- wherein R7 and R8 are independently selected from R3, wherein R3 is as previously defined;
- or
- (ii) -Q- taken together with the two carbon atoms it is attached to is selected from the group consisting of:
- a. cycloalkylene;
- b. cycloalkenylene;
- and
- c. heterocycloalkylene;
- and
- (f) —CH2—C(R11)(R12)—CH2—CH2—;
- wherein R11 and R12 taken together with the carbon atom to which they are attached are selected from the group consisting of:
- (i) C═O;
- (ii) C(OR1a)(OR2a), where R1a and R2a are independently R1 or taken together are —(CH2)m—, and where m is 2 or 3;
- (iii) C(SR1a)(SR2a), where R1a and R2a are as previously defined;
- (iv) C═CHR3, where R3 is as previously defined;
- (v) C═N—O—R3, where R3 is as previously defined;
- (vi) C═NNHR3, where R3 is as previously defined;
- (vii) C═NNHC(O)R3, where R3 is as previously defined;
- (viii) C═NNHC(O)NR4R5, where R4 and R5 are as previously defined;
- (ix) C═NNHS(O)2R9, where R9 is as previously defined;
- (x) C═NNHR13, where R13 is as previously defined;
- and
- (xi) C═NR9, where R9 is as previously defined;
- (g) —C(R14)(R15)—CH2—;
- wherein R14 is:
- (i) —ORp, where Rp is previously defined;
- (ii) —R1, where R1 is as previously described;
- (iii) —R2, where R2 is as previously described;
- (iv) —OR1, where R1 is as previously defined;
- (v) —OR2, where R2 is previously defined;
- (vi) —S(O)nR9, where n and R9 are as previously defined;
- (vii) —NHC(O)R9, where R9 is as previously defined;
- (viii) —NHC(O)NHR9, where R9 is as previously defined;
- (ix) —NHS(O)2R9, where R9 is as previously defined;
- (x) —NR4R5, where R4 and R5 are as previously defined;
- (xi) —NHR13, where R13 is previously defined;
- and
- R15 is:
- (i) deuterium;
- (ii) halogen;
- (iii) —OH;
- (iv) —R1, where R1 is as previously defined;
- (v) —R2, where R2 is as previously defined;
- or
- (vi) —ORp, where Rp is as previously defined, provided that when R15 is halogen, —OH or ORp, R14 is R1 or R2, where R1 and R2 are previously defined;
- or, alternatively, R14 and R15 taken together with the carbon atom to which they are attached are:
- (i) C═O;
- (ii) C(OR1a)(OR2a), where R1a and R2a are independently R1 or taken together are —(CH2)m—, and where m is 2 or 3;
- (iii) C(SR1a)(SR2a), where R1a and R2a are as previously defined;
- (iv) C═CHR9, where R9 is as previously defined;
- (v) C═N—O—R9, where R9 is as previously defined;
- (vi) C═NNHR9, where R9 is as previously defined;
- (vii) C═NNHC(O)R9, where R9 is as previously defined;
- (viii) C═NNHC(O)NHR9, where R9 is as previously defined;
- (ix) C∇NNHS(O)2R9, where R9 is as previously defined;
- (x) C═NNHR9, where R9 is as previously defined;
- or
- (xi) C═NR9, where R9 is as previously defined;
- (h) —CH2—C(R14)(R15)—CH2—;
- wherein R14 and R15 as previously defined;
- G and W are independently selected from:
- (a) hydrogen;
- (b) R10, where R10 is C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, containing 0, 1, 2, or 3 heteroatoms, optionally substituted with one or more substituents selected from:
- (1) halogen;
- (2) aryl;
- (3) substituted-aryl;
- (4) heteroaryl;
- (5) substituted-heteroaryl;
- (6) —O—C1-C6-alkyl-R9, where R9 is as previously defined;
- and
- (7) —N(R1R5), where R4 and R5 are as previously defined;
- (c) —C(O)R9, where R9 is as previously defined;
- (d) —C(O)O—R9, where R9 is as previously defined;
- and
- (e) —C(O)N(R4R5), where R4 and R5 are as previously defined;
- Or, alternatively, G and W are taken together to form either a carbonyl or a methylene group,
- L is:
- (a) —CH2CH3;
- (b) —CH(OH)CH3;
- (c) -R1, where R1 is as previously defined,
- D is —N(R19)CH2—, —N(R20)C(O)—, or —N═C(OR20)—, wherein R20 is R9 where R9 is as previously defined;
- R19 is
- (a) hydrogen;
- (b) —C1-C12-alkyl, C2C12-alkenyl, or C2C12alkynyl, containing 0, 1, 2, or 3 heteroatoms, all optionally substituted with one or more substituents independently selected from:
- i) halogen;
- ii) —OR1, wherein R1 is as previously defined;
- iii) —OR2, wherein R2 is as previously defined;
- iv) —NR4R5, where R4 and R5 as previously defined or alternatively R4 and R5, together with the atom to which they are attached, form a heterocycloalkyl or substituted heterocycloalkyl moiety;
- v) ═N—O—R9, where R9 is as previously defined;
- vi) —R1, where R1 is as previously defined;
- vii) —C3-C8-cycloalkyl;
- viii) substituted —C3-C8-cycloalkyl;
- ix) heterocycloalkyl;
- x) substituted heterocycloalkyl;
- xi) —NHC(O)R9, where R9 is as previously defined;
- xii) —NHC(O)OR9, where R9 is as previously defined;
- xiii) —NHC(O)NR4R5, where R4 and R5 are as previously defined;
- xiv) —OC(O)NR4R5, where R4 and R5 are as previously defined;
- xv) —OC(O)R9, where R9 is as previously defined;
- xvi) —OC(O)OR9, where R9 is as previously defined;
- xvii) —OC(O)NR4R5, where R4 and R5 are as previously defined,
- xviii) —C(O)R9, where R9 is as previously defined,
- xix) —CO2R9, where R9 is as previously defined, or
- xx) —C(O)NR4R5, where R4 and R5 are as previously defined;
- Alternatively, D when taken together with G to form a moiety of the following structure:
- wherein L, V, W and R2′ are as previously defined and P is C1-C6 alkyl optionally substituted with one or more substituents selected from the group consisting of:
- a) R1, where R1 is as previously defined;
- b) R2, where R2 is as previously defined;
- c) heterocycloalkyl,
- d) hydroxyl,
- e) C1-C6-alkoxy,
- f) Halogen, and
- g) NR4R5 where R4 and R5 are as previously defined,
- X is hydrogen;
- Y is
- (a) hydrogen;
- (b) —OH;
- (c) —ORp, where Rp is as previously defined;
- (d) —OR9, where R9 is as previously defined;
- (e) —OC(O)R9, where R9 is as previously defined;
- (f) —OC(O)NHR9, where R9 is as previously defined;
- (g) —S(O)nR9, where n and R9 are as previously defined;
- where R3″ is selected from hydrogen or methyl and R4″ is selected from:
- (1) hydrogen;
- (2) Rp, where Rp is as previously defined;
- or
- (3) —C(O)(CH2)r-E-R9, wherein R9 is as previously defined, r =1-6 and E is absent or -U(CH2)qU′-, where q =an integer from 2 to 8, and U and U′ are independently selected from:
- i) —N(R9)—, where R9 is as previously defined;
- ii) —O—;
- iii) —S(O)n—, where n =0, 1, or 2;
- iv) —N(R9)C(O)—, where R9 is as previously defined;
- v) —C(O)N(R9)—, where R9 is as previously defined;
- or
- vi) —N[C(O)R9]—, where R9 is as previously defined;
- and
- Alternatively, X and Y taken together are oxo;
- Z is
- (a) hydrogen;
- (b) methyl;
- or
- (c) halogen;
- and
- R2′ is hydrogen or Rp, where Rp, is as previously defined.
Dependencies are inferred from the claim text.